Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies Portfolio News / By Karina Tin July 27, 2023 Synthekine Doses First Patient in Phase 1 Clinical Trial of Orthogonal IL-2 and CD19 CAR-T Combination Therapy, STK-009 + SYNCAR-001, for Treatment of CD19+ Hematologic Malignancies Read More »
Circle Pharma Strengthens Its Executive Leadership Team With Two Senior Appointments in Clinical Development Portfolio News / By Karina Tin July 26, 2023 Circle Pharma Strengthens Its Executive Leadership Team With Two Senior Appointments in Clinical Development Read More »
Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B Portfolio News / By Karina Tin July 19, 2023 Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B Read More »
Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer Portfolio News / By Karina Tin July 17, 2023 Atavistik Bio Appoints Bryan Stuart as Chief Executive Officer Read More »
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin July 13, 2023 Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Read More »
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing Portfolio News / By Karina Tin June 26, 2023 ORIC Pharmaceuticals Announces $85 Million Private Placement Financing Read More »
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions Portfolio News / By Karina Tin June 23, 2023 Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions Read More »
Escient Pharmaceuticals Announces Positive Results From Phase 1 Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders Portfolio News / By Karina Tin June 20, 2023 Escient Pharmaceuticals Announces Positive Results From Phase 1 Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders Read More »
Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy Portfolio News / By Karina Tin June 15, 2023 Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy Read More »
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications Portfolio News / By Karina Tin June 14, 2023 Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications Read More »
